Industry Strength Score
54/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NUVALENT INC-A (NUVL) Stock Price & Overview
NASDAQ:NUVL • US6707031075
Current stock price
99.04 USD
-1.24 (-1.24%)
At close:
99.3208 USD
+0.28 (+0.28%)
After Hours:
The current stock price of NUVL is 99.04 USD. Today NUVL is down by -1.24%. In the past month the price decreased by -6.06%. In the past year, price increased by 27.86%.
NUVL Key Statistics
52-Week Range63.555 - 113.015
Current NUVL stock price positioned within its 52-week range.
1-Month Range97.77 - 109.53
Current NUVL stock price positioned within its 1-month range.
- Market Cap
- 7.787B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.85
- Dividend Yield
- N/A
NUVL Stock Performance
Today
-1.24%
1 Week
-5.22%
1 Month
-6.06%
3 Months
-3.74%
Longer-term
6 Months -0.28%
1 Year +27.86%
2 Years +50.93%
3 Years +135.25%
5 Years N/A
10 Years N/A
NUVL Stock Chart
NUVL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NUVL. When comparing the yearly performance of all stocks, NUVL turns out to be only a medium performer in the overall market: it outperformed 62.55% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NUVL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NUVL. While NUVL has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NUVL Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.58
Revenue Reported
EPS Surprise -4.98%
Revenue Surprise %
NUVL Forecast & Estimates
24 analysts have analysed NUVL and the average price target is 143.14 USD. This implies a price increase of 44.53% is expected in the next year compared to the current price of 99.04.
Analysts
Analysts85.83
Price Target143.14 (44.53%)
EPS Next Y4.55%
Revenue Next YearN/A
NUVL Index Membership
NUVL is currently included in the following stock indexes tracked on ChartMill.
NUVL Financial Highlights
Over the last trailing twelve months NUVL reported a non-GAAP Earnings per Share(EPS) of -5.85. The EPS decreased by -50% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-425.38M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.11% | ||
| ROE | -34.08% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-50.48%
Sales Q2Q%N/A
EPS 1Y (TTM)-50%
Revenue 1Y (TTM)N/A
NUVL Ownership
Ownership
Inst Owners109.17%
Shares78.62M
Float69.48M
Ins Owners0.54%
Short Float %6.6%
Short Ratio7.85
NUVL Industry Overview
NUVL operates in the Biotechnology sub-industry within the Health Care sector. This group contains 412 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 412
- New Highs
- 4.6%
- New Lows
- 4.6%
- Average ROE
- 47%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.9%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.1
NUVL Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NUVL
Company Profile
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Company Info
IPO: 2021-07-29
NUVALENT INC-A
One Broadway, 14Th Floor
Cambridge MASSACHUSETTS US
CEO: James R. Porter
Employees: 228
Phone: 13026587581
NUVALENT INC-A / NUVL FAQ
What does NUVALENT INC-A do?
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Can you provide the latest stock price for NUVALENT INC-A?
The current stock price of NUVL is 99.04 USD. The price decreased by -1.24% in the last trading session.
Does NUVALENT INC-A pay dividends?
NUVL does not pay a dividend.
How is the ChartMill rating for NUVALENT INC-A?
NUVL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is NUVALENT INC-A worth?
NUVALENT INC-A (NUVL) has a market capitalization of 7.79B USD. This makes NUVL a Mid Cap stock.
What is the Short Interest ratio of NUVALENT INC-A (NUVL) stock?
The outstanding short interest for NUVALENT INC-A (NUVL) is 6.6% of its float.